Homology Medicines Inc (FRA:35H)

€ 14.94 0.000001 (0%) Market Cap: 2.78 Mil Enterprise Value: -72.11 Mil PE Ratio: 0 PB Ratio: 0.04 GF Score: 32/100

Homology Medicines Inc to Announce Encouraging First Dose Level Initial Data Call Transcript
Jul 27, 2023
Homology Medicines Inc Annual Shareholders Meeting Transcript
Jun 14, 2023
Homology Medicines Inc at Stifel Healthcare Conference Transcript
Nov 15, 2022
Homology Medicines Inc Annual Shareholders Meeting Transcript
Jun 15, 2022
Homology Medicines Inc ASGCT Symposium Transcript
May 18, 2022
Homology Medicines Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 11, 2022
Homology Medicines Inc to Discuss Transaction with Oxford Biomedica and Provide an Update on Clinical Programs and Product Pipeline Transcript
Jan 28, 2022
Homology Medicines Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 08, 2021
Homology Medicines Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) Transcript
Oct 13, 2021
Homology Medicines Inc at Bank of America NAPA Healthcare Conference Transcript
Jun 15, 2021
Homology Medicines Inc Corporate and Pipeline Updates Transcript
May 13, 2021
Homology Medicines Inc At Cell Gene Meeting on the Mesa Transcript
Jan 08, 2021
Homology Medicines Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) Transcript
Oct 12, 2020
Homology Medicines Inc To Host Emerging Therapies and Clinical Trials Event Transcript
Aug 25, 2020

Homology Medicines Inc Corporate and Pipeline Updates Transcript

May 13, 2021 / 12:15PM GMT

Release Date Price: €94.5 (-0.94%)

Transcript 10-Q

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Homology Medicines Corporate and Pipeline Update Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your host, Theresa McNeely, Chief Communications Officer and Patient Advocate at Homology. Please go ahead.

Theresa McNeely

Homology Medicines, Inc. - Chief Communications Officer & Patient Advocate

Thank you, and welcome, everyone, to our conference call today. We're excited to share with you data highlights from this week's ASGCT and to provide more details on our new GTx-mAb platform as well as our other programs.

But before I begin, I'd like to remind everyone that we'll be making some statements about the company's future expectations, plans and prospects, which constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.